Literature DB >> 22076650

Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.

Thomas Schmidt1, Isabel Ben-Batalla, Alexander Schultze, Sonja Loges.   

Abstract

Ample clinical and preclinical evidence indicates that macrophages interact with tumor cells as well as with virtually all populations of host cells present in the tumor microenvironment. This crosstalk can strongly promote malignancy, but also has in principle the potential to inhibit tumor growth. Thus, it is of the utmost importance to improve our understanding of the mechanisms driving the pro- and antimalignant behavior of tumor-associated macrophages (TAMs) in order to develop better anticancer therapies. In this review, we discuss the biological consequences of reciprocal interactions between TAMs, cancer cells, endothelial cells, fibroblasts and other leukocyte subfractions within tumors. It was recently elucidated that tumors specifically educate macrophages to secrete growth arrest-specific gene 6 (Gas6), the common ligand of the Tyro3, Axl, Mer receptor (TAMR) family. In turn, Gas6 fosters tumor growth by promoting cancer cell proliferation. Therefore, the Gas6-TAMR axis might represent a novel target for disrupting tumor-macrophage crosstalk. We summarize here what is known about TAMR and their ligands in (human) cancer biology. In order to shed more light on the role of macrophages in human cancer, we additionally provide an overview of what is currently known about the prognostic impact of TAMs in human cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22076650     DOI: 10.1007/s00018-011-0863-7

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  226 in total

1.  Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells.

Authors:  A M Healy; J J Schwartz; X Zhu; B E Herrick; B Varnum; H W Farber
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-06       Impact factor: 5.464

2.  Differential expression of the ufo/axl oncogene in human leukemia-lymphoma cell lines.

Authors:  C Challier; C C Uphoff; J W Janssen; H G Drexler
Journal:  Leukemia       Date:  1996-05       Impact factor: 11.528

Review 3.  Immunobiology of the TAM receptors.

Authors:  Greg Lemke; Carla V Rothlin
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

4.  p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance.

Authors:  Alessandra Saccani; Tiziana Schioppa; Chiara Porta; Subhra K Biswas; Manuela Nebuloni; Luca Vago; Barbara Bottazzi; Mario P Colombo; Alberto Mantovani; Antonio Sica
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

5.  Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12.

Authors:  Antonella Rigo; Michele Gottardi; Alberto Zamò; Pierluigi Mauri; Massimiliano Bonifacio; Mauro Krampera; Ernesto Damiani; Giovanni Pizzolo; Fabrizio Vinante
Journal:  Mol Cancer       Date:  2010-10-14       Impact factor: 27.401

Review 6.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

7.  Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.

Authors:  Rachel M A Linger; Deborah DeRyckere; Luis Brandão; Kelly K Sawczyn; Kristen M Jacobsen; Xiayuan Liang; Amy K Keating; Douglas K Graham
Journal:  Blood       Date:  2009-07-30       Impact factor: 22.113

8.  The receptor tyrosine kinase MerTK activates phospholipase C gamma2 during recognition of apoptotic thymocytes by murine macrophages.

Authors:  Jill C Todt; Bin Hu; Jeffrey L Curtis
Journal:  J Leukoc Biol       Date:  2004-01-02       Impact factor: 4.962

9.  A genomic screen identifies TYRO3 as a MITF regulator in melanoma.

Authors:  Shoutian Zhu; Heiko Wurdak; Yan Wang; Anna Galkin; Haiyan Tao; Jie Li; Costas A Lyssiotis; Feng Yan; Buu P Tu; Loren Miraglia; John Walker; Fanxiang Sun; Anthony Orth; Peter G Schultz; Xu Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-23       Impact factor: 11.205

10.  Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase.

Authors:  Philip L Cohen; Roberto Caricchio; Valsamma Abraham; Todd D Camenisch; J Charles Jennette; Robert A S Roubey; H Shelton Earp; Glenn Matsushima; Elizabeth A Reap
Journal:  J Exp Med       Date:  2002-07-01       Impact factor: 14.307

View more
  16 in total

1.  Cyclin D1b induces changes in the macrophage phenotype resulting in promotion of tumor metastasis.

Authors:  Yuxue Wang; Yi Liu; Lei Xiang; Lintao Han; Xiaowei Yao; Yibing Hu; Fenghua Wu
Journal:  Exp Biol Med (Maywood)       Date:  2021-09-13

2.  Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.

Authors:  J S Waizenegger; I Ben-Batalla; N Weinhold; T Meissner; M Wroblewski; M Janning; K Riecken; M Binder; D Atanackovic; H Taipaleenmaeki; D Schewe; S Sawall; V Gensch; M Cubas-Cordova; A Seckinger; W Fiedler; E Hesse; N Kröger; B Fehse; D Hose; B Klein; M S Raab; K Pantel; C Bokemeyer; S Loges
Journal:  Leukemia       Date:  2014-08-08       Impact factor: 11.528

3.  Elevated Serum Gas6 Is a Novel Prognostic Biomarker in Patients with Oral Squamous Cell Carcinoma.

Authors:  Tao Jiang; Guoxia Liu; Lin Wang; Hongchen Liu
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

Review 4.  AXL kinase as a novel target for cancer therapy.

Authors:  Xiaoliang Wu; Xuewen Liu; Sanjay Koul; Chang Youl Lee; Zhenfeng Zhang; Balazs Halmos
Journal:  Oncotarget       Date:  2014-10-30

5.  A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.

Authors:  Ozhan Ocal; Victor Pashkov; Rahul K Kollipara; Yalda Zolghadri; Victoria H Cruz; Michael A Hale; Blake R Heath; Alex B Artyukhin; Alana L Christie; Pantelis Tsoulfas; James B Lorens; Galvin H Swift; Rolf A Brekken; Thomas M Wilkie
Journal:  Dis Model Mech       Date:  2015-10-01       Impact factor: 5.758

6.  TAM receptors Tyro3 and Mer as novel targets in colorectal cancer.

Authors:  Robin Schmitz; Aida Freire Valls; Rosario Yerbes; Sophie von Richter; Christoph Kahlert; Sonja Loges; Jürgen Weitz; Martin Schneider; Carmen Ruiz de Almodovar; Alexis Ulrich; Thomas Schmidt
Journal:  Oncotarget       Date:  2016-08-30

Review 7.  The Emerging Role of TYRO3 as a Therapeutic Target in Cancer.

Authors:  Sherri K Smart; Eleana Vasileiadi; Xiaodong Wang; Deborah DeRyckere; Douglas K Graham
Journal:  Cancers (Basel)       Date:  2018-11-29       Impact factor: 6.639

8.  Targeting Axl with an high-affinity inhibitory aptamer.

Authors:  Laura Cerchia; Carla L Esposito; Simona Camorani; Anna Rienzo; Loredana Stasio; Luigi Insabato; Andrea Affuso; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2012-08-21       Impact factor: 11.454

9.  GAS6 expression identifies high-risk adult AML patients: potential implications for therapy.

Authors:  Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield; Susan P Whitman; Jessica Kohlschmidt; Kati Maharry; Stefano Volinia; Krzysztof Mrózek; Deedra Nicolet; Sebastian Schwind; Heiko Becker; Klaus H Metzeler; Jason H Mendler; Ann-Kathrin Eisfeld; Andrew J Carroll; Bayard L Powell; Thomas H Carter; Maria R Baer; Jonathan E Kolitz; Il-Kyoo Park; Richard M Stone
Journal:  Leukemia       Date:  2013-12-11       Impact factor: 11.528

10.  Gas6/MerTK signaling is negatively regulated by NF-κB and supports lung carcinogenesis.

Authors:  Sergey V Novitskiy; Rinat Zaynagetdinov; Georgii Vasiukov; Sergey Gutor; Wei Han; Ana Serezani; Anton Matafonov; Linda A Gleaves; Taylor P Sherrill; Vasiliy V Polosukhin; Timothy S Blackwell
Journal:  Oncotarget       Date:  2019-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.